Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 1/2 8Phase 3 3Phase 1 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Cisplatin 13Paclitaxel 11Cyclophosphamide 11Doxorubicin 10Magnetic Resonance Spectroscopy 9Gemcitabine 9Prednisone 8Docetaxel 8Specimen Handling 7Oxaliplatin 7Carboplatin 7Vincristine 6Etoposide 6Capecitabine 6pembrolizumab 5Rituximab 5Radiotherapy 5Leucovorin 5Cytarabine 5Bevacizumab 5atezolizumab 4Trastuzumab 4Platinum 4Nivolumab 4Fluorouracil 4Dexamethasone 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Watchful Waiting 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × cemiplimab × Clear all
NCT05785767 2026-01-22

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Regeneron Pharmaceuticals

Phase 2/3 Active not recruiting
850 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Regeneron Pharmaceuticals

Phase 2/3 Active not recruiting
950 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡